Galenica (GALE) Stock Overview
Provides healthcare services in Switzerland and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 3/6 |
GALE Community Fair Values
Create NarrativeSee what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Galenica AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 87.15 |
| 52 Week High | CHF 103.00 |
| 52 Week Low | CHF 81.10 |
| Beta | 0.29 |
| 1 Month Change | 3.01% |
| 3 Month Change | 1.93% |
| 1 Year Change | -1.47% |
| 3 Year Change | 21.80% |
| 5 Year Change | 27.88% |
| Change since IPO | 102.67% |
Recent News & Updates
Narrative Update • Jun 16
GALE: UBS Upgrade And 2026 Guidance Confirmation Will Support Steady Outlook
Analysts have nudged their price targets on Galenica higher to CHF 87.20, citing slightly firmer expectations for revenue growth, profit margins and future P/E assumptions reflected in recent research, including the latest UBS upgrade. What's in the News Galenica confirmed its earnings guidance for the 2026 financial year, maintaining expected sales growth in a range of 5% to 7%.Narrative Update • Jun 01
GALE: Upgraded Rating And Dividend Policy Will Support A Steady Outlook
Analysts have slightly adjusted their view on Galenica, trimming the fair value estimate from CHF 88.00 to CHF 87.20. This reflects small changes in discount rate, growth and margin assumptions that result in a modestly lower projected future P/E, while still supporting a recent upgrade highlighted in Street research.Narrative Update • Apr 29
GALE: Dividend Outlook And Job Cuts Will Support A Steady Forward View
Analysts now estimate Galenica's fair value at CHF 88.00, matching the previous CHF 88.00 and reflecting largely unchanged assumptions on discount rate, revenue growth, profit margin and future P/E. What's in the News Annual dividend of CHF 1.25 per share announced, with payment scheduled for April 27, 2026, ex date on April 23, 2026, and record date on April 24, 2026 (Key Developments).Narrative Update • Apr 13
GALE: Dividend Plans And EBIT Outlook Will Support Steady Forward View
Analysts have kept their Galenica fair value target steady at CHF 88.00, reflecting unchanged assumptions on discount rate, revenue growth, profit margin and future P/E, and indicating that their overall view of the stock’s valuation remains the same following recent research. What's in the News Galenica announced an annual dividend of CHF 1.25 per share, with payment scheduled for April 27, 2026, ex date on April 23, 2026, and record date on April 24, 2026 (Key Developments).Recent updates
Narrative Update • Jun 16
GALE: UBS Upgrade And 2026 Guidance Confirmation Will Support Steady Outlook
Analysts have nudged their price targets on Galenica higher to CHF 87.20, citing slightly firmer expectations for revenue growth, profit margins and future P/E assumptions reflected in recent research, including the latest UBS upgrade. What's in the News Galenica confirmed its earnings guidance for the 2026 financial year, maintaining expected sales growth in a range of 5% to 7%.Narrative Update • Jun 01
GALE: Upgraded Rating And Dividend Policy Will Support A Steady Outlook
Analysts have slightly adjusted their view on Galenica, trimming the fair value estimate from CHF 88.00 to CHF 87.20. This reflects small changes in discount rate, growth and margin assumptions that result in a modestly lower projected future P/E, while still supporting a recent upgrade highlighted in Street research.Narrative Update • Apr 29
GALE: Dividend Outlook And Job Cuts Will Support A Steady Forward View
Analysts now estimate Galenica's fair value at CHF 88.00, matching the previous CHF 88.00 and reflecting largely unchanged assumptions on discount rate, revenue growth, profit margin and future P/E. What's in the News Annual dividend of CHF 1.25 per share announced, with payment scheduled for April 27, 2026, ex date on April 23, 2026, and record date on April 24, 2026 (Key Developments).Narrative Update • Apr 13
GALE: Dividend Plans And EBIT Outlook Will Support Steady Forward View
Analysts have kept their Galenica fair value target steady at CHF 88.00, reflecting unchanged assumptions on discount rate, revenue growth, profit margin and future P/E, and indicating that their overall view of the stock’s valuation remains the same following recent research. What's in the News Galenica announced an annual dividend of CHF 1.25 per share, with payment scheduled for April 27, 2026, ex date on April 23, 2026, and record date on April 24, 2026 (Key Developments).Narrative Update • Mar 28
GALE: Dividend Plans And EBIT Guidance Will Support Fairly Balanced Outlook
Analysts have nudged their price target for Galenica slightly higher to CHF 88.00 from CHF 87.17, reflecting small adjustments to long term revenue growth, profit margin assumptions, and the future P/E multiple. What's in the News Galenica issued earnings guidance for 2026, with expected sales growth in a range of 5% to 7% (company guidance).Narrative Update • Mar 13
GALE: Future Dividend Plans And EBIT Outlook Will Support Balanced View
Analysts have nudged their Galenica price target slightly higher to CHF 87.17 from CHF 86.67, reflecting small model adjustments related to revenue growth, margins and future P/E assumptions. What's in the News Galenica AG announced an annual dividend of CHF 1.2500 per share, with payment scheduled for April 27, 2026, an ex date on April 23, 2026, and a record date on April 24, 2026 (Key Developments).Narrative Update • Feb 27
GALE: Confirmed 2025 EBIT Increase And Fair Value Suggest Balanced Outlook
Analysts have made a small upward adjustment to their Galenica price target to CHF 86.67. This reflects fine tuning of fair value inputs and slightly revised assumptions around future P/E, revenue growth and profit margins.Narrative Update • Feb 12
GALE: Confirmed 2025 EBIT Outlook Will Sustain Limited Future Upside
Analysts have maintained their Galenica fair value estimate at CHF 86.50. They have made only slight adjustments to inputs such as the discount rate and assumed future P/E, which supports a broadly unchanged price target narrative.Narrative Update • Jan 27
GALE: Modest EBIT Guidance And M&A Synergies Will Limit Future Upside
Analysts have nudged their fair value estimate for Galenica up to €86.50 from €86.17. This reflects slightly updated assumptions on revenue growth, profit margins and future P/E expectations.Analysis Article • Jan 22
Galenica AG's (VTX:GALE) Business Is Trailing The Market But Its Shares Aren't
With a price-to-earnings (or "P/E") ratio of 24.9x Galenica AG ( VTX:GALE ) may be sending bearish signals at the...Narrative Update • Jan 12
GALE: New Consultation Concept Will Signal Limited Upside Despite Margin Tweaks
Analysts have modestly adjusted their price target for Galenica to reflect an unchanged fair value of €86.17, slightly revised margin expectations, and a small tweak to future P/E assumptions. This has led to a measured recalibration rather than a major shift in outlook.Narrative Update • Dec 14
GALE: New Pharmacy Format And Digital Focus Will Support Steady Outlook
Analysts have maintained their price target for Galenica at CHF 86.17, reflecting unchanged assumptions on discount rate, revenue growth, profit margin, and future price-to-earnings multiple, and signaling continued confidence in the company’s steady fundamental outlook. What's in the News Issued 2025 guidance targeting sales growth of 4% to 6% and an EBIT increase of 10% to 12%, underlining expectations for accelerated profitability (company guidance) Launched a pilot pharmacy concept at the Amavita pharmacy in Zurich's Glattzentrum, focused on enhanced consultations and customer experience to respond to evolving patient needs (company announcement) Redesigned Amavita Glattzentrum to include express checkouts, fully private consultation rooms and semi private consultation areas equipped with screens for joint product and service review (company announcement) Positioned the new pharmacy concept as a core element of Galenica's strategy to better connect digital and in store offerings, reflecting the trend that about 80% of customers research online before visiting a pharmacy (company announcement) Valuation Changes Fair Value: unchanged at CHF 86.17, indicating no revision to the intrinsic value estimate.Analysis Article • Dec 03
Is There An Opportunity With Galenica AG's (VTX:GALE) 36% Undervaluation?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Galenica fair value estimate is CHF145 Current share price of...Narrative Update • Nov 28
GALE: Digital Service Integration And Pharmacy Redesign Will Drive Steady Performance Ahead
Analysts have maintained their fair value estimate for Galenica at CHF 86.17. They cite modest increases in projected revenue growth and profit margin as key supporting factors.Narrative Update • Nov 13
GALE: Digital Integration And New Pharmacy Model Will Shape Future Performance
Analysts have raised their price target for Galenica, increasing the fair value estimate from CHF 85.50 to CHF 86.17. This adjustment is attributed to improved revenue growth and modest enhancements in profit margin projections.Analysis Article • Nov 05
Here's Why We Think Galenica (VTX:GALE) Is Well Worth Watching
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Narrative Update • Oct 30
GALE: Stable Outlook As Digital And In-Store Investments Will Support 2025 Guidance
Galenica's analyst price target remains unchanged at CHF 85.50. Analysts cite minimal revisions to growth and margin assumptions since the previous update.Analysis Article • Oct 23
The Returns At Galenica (VTX:GALE) Aren't Growing
What trends should we look for it we want to identify stocks that can multiply in value over the long term? In a...Narrative Update • Oct 16
Expanding Diagnostics And Digital Health Will Transform Healthcare Markets
Analysts have raised their price target for Galenica from CHF 84.20 to CHF 85.50. They cite updated financial models and a slightly improved near-term outlook, despite only minor adjustments to underlying growth forecasts.Analysis Article • Sep 21
Some Shareholders Feeling Restless Over Galenica AG's (VTX:GALE) P/E Ratio
Galenica AG's ( VTX:GALE ) price-to-earnings (or "P/E") ratio of 21.9x might make it look like a sell right now...Analysis Article • Aug 25
We Think Galenica (VTX:GALE) Can Stay On Top Of Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Jul 27
Here's Why We Think Galenica (VTX:GALE) Is Well Worth Watching
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
New Narrative • Mar 16
Home Care Expansion And Digital Initiatives Will Drive Future Success
Expansion in home care and pharmacy digitization promises revenue growth and improved market positioning through service integration and enhanced customer engagement.Shareholder Returns
| GALE | CH Healthcare | CH Market | |
|---|---|---|---|
| 7D | -1.5% | -0.2% | -0.7% |
| 1Y | -1.5% | -4.2% | 14.0% |
Return vs Industry: GALE matched the Swiss Healthcare industry which returned -2.1% over the past year.
Return vs Market: GALE underperformed the Swiss Market which returned 14.9% over the past year.
Price Volatility
| GALE volatility | |
|---|---|
| GALE Average Weekly Movement | 2.0% |
| Healthcare Industry Average Movement | 4.9% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in CH Market | 7.6% |
| 10% least volatile stocks in CH Market | 2.2% |
Stable Share Price: GALE has not had significant price volatility in the past 3 months compared to the Swiss market.
Volatility Over Time: GALE's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1927 | 6,577 | Marc Werner | www.galenica.com |
Galenica AG provides healthcare services in Switzerland and internationally. It operates through two segments, Products & Care, and Logistics & IT. The Products & Care segment operates and manages pharmacies and partner pharmacies under the Amavita, Sun Store, and Coop Vitality brands, as well as covers specialty pharmacy mediservice.
Galenica AG Fundamentals Summary
| GALE fundamental statistics | |
|---|---|
| Market cap | CHF 4.34b |
| Earnings (TTM) | CHF 182.71m |
| Revenue (TTM) | CHF 4.15b |
23.8x
P/E Ratio1.0x
P/S RatioIs GALE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GALE income statement (TTM) | |
|---|---|
| Revenue | CHF 4.15b |
| Cost of Revenue | CHF 3.64b |
| Gross Profit | CHF 504.57m |
| Other Expenses | CHF 321.86m |
| Earnings | CHF 182.71m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Aug 06, 2026
| Earnings per share (EPS) | 3.67 |
| Gross Margin | 12.17% |
| Net Profit Margin | 4.41% |
| Debt/Equity Ratio | 53.7% |
How did GALE perform over the long term?
See historical performance and comparisonDividends
2.9%
Current Dividend Yield68%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/23 16:54 |
| End of Day Share Price | 2026/07/23 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Galenica AG is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alexander Berglund | BofA Global Research |
| Jan Koch | Deutsche Bank |
| Yi-Dan Wang | Deutsche Bank |